

Bexion Pharmaceuticals, Inc. Welcomes New Chief Financial Officer



Seasoned BIO/Pharma Executive adds finance, strategic capital access and public market readiness to the management team

Bexion Pharmaceuticals, Inc., a mid-stage biopharmaceutical company developing innovative therapies for cancers and chemotherapy induced peripheral neuropathy (CIPN), announced that Ms. Joyce LaViscount has joined the Company's leadership team as Chief Financial Officer (CFO).

Ms. LaViscount brings over 30 years of experience spanning start-up organizations to Fortune 100 companies with diverse leadership roles across finance, accounting, and operations. Prior to joining Bexion Pharmaceuticals, Joyce served as Chief Financial Officer for Panavance Therapeutics, a clinical stage pharmaceutical company focusing on a novel oncology therapeutic. Prior to Panavance, Ms.

LaViscount served as CFO and COO for Helius Medical Technologies raising over US\$110M to fund corporate development and secure listings on both Nasdaq and Toronto exchanges. Her foundation in the industry is based on more than 20 years of roles of increasing responsibility with Pfizer/Pharmacia, Bristol-Myers Squibb, and Endo Pharmaceuticals.

Scott Shively, Bexion's Chief Executive Officer and President, commented, "Joyce has a proven track record of results-driven leadership, strategic thinking and financial acumen, and has proven experience in both private and public company settings. We look forward to her joining our team and contributing to Bexion's continued progression as a company as we progress our lead product BXQ-350 and continue to build our capital structure."

"I am excited to join the experienced Bexion leadership team at a pivotal point in the organization's growth and look forward to leading the evolution of our capital structure and financial operating environment to further the development of our promising pipeline," said Joyce LaViscount. "Bexion stood out to me as a truly science driven organization focused on delivering transformative therapies for patients, including our lead candidate BXQ-350, which if approved could be life-changing for patients living with colorectal cancer and other solid tumors."

Source: [Bexion Pharmaceuticals](#)

Published on : Thu, 2 Jun 2022